Showing results (91-100 of 144) with videos related to
Sort By:
Pageof 15
Breast Cancer Research and Treatment|February 10, 2025
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancerNan Chen, Margarite Matossian, Poornima Saha, et al.Gynecologic Oncology|February 9, 2025
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trialIris L Romero, Ernst Lengyel, Andrea E Wahner Hendrickson, et al.Journal of Pain Research|December 24, 2024
Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment (C-PAIN): A Randomized Trial of Preemptive CYP2D6 Genotyping in Cancer Palliative CareYoungwoo Cho, Theodore Karrison, Matthew M Jack, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2014
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancerFederico Innocenti, Richard L Schilsky, Jacqueline Ramírez, et al.The Oncologist|August 1, 2013
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesisSumita S Bhatta, Kristen E Wroblewski, Kelly L Agarwal, et al.Pharmacogenetics and Genomics|September 27, 2021
Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative careTien M Truong, Jeffrey L Apfelbaum, Emily Schierer, et al.Blood Advances|August 16, 2022
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantationJames Godfrey, Hongtao Liu, Jovian Yu, et al.Breast Cancer Research and Treatment|August 8, 2025
Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancerErica M Stringer-Reasor, Poornima Saha, Masha Kocherginsky, et al.Nature Communications|July 6, 2026
A virulent bacterial signature is associated with the development of recurrence following colorectal cancer surgeryMeejeon Roh, Bidisha Barat, Jack A Gilbert, et al.Cancer Immunology Research|January 24, 2014
Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancerDavid C Binder, Boris Engels, Ainhoa Arina, et al.Pageof 15